CoChat

Alzheimer's Disease: Treatment Strategies and Their Limitations.

Open access
Passeri, Elodie, Elkhoury, Kamil, Morsink, Margaretha, Broersen, Kerensa, Linder, Michel, Tamayol, Ali, Malaplate, Catherine, Yen, Frances T., Arab-Tehrany, Elmira · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 274 of the 279 references it cites were found in a registry or an index; 114 of the 190 sources its claims cite were checked for support.

Abstract

Current drug treatments have only symptomatic effects, and disease-modifying treatments are not yet available. Drug delivery to the central nervous system remains a complex process and represents a challenge.

Overview

CoChat Summary

TL;DR

This review argues that Alzheimer’s disease is a progressive, multifactorial disorder for which current drugs are only symptomatic and not curative, making prevention and earlier intervention the main priorities. It emphasizes modifiable risk factors, lipid-based prevention, and soft nanoparticles—especially liposomes and exosomes—as promising ways to improve delivery across the blood–brain barrier.

Key findings

  • AD is described as a continuum with preclinical, MCI due to AD, and dementia stages; the first neuropathological signs can appear 15–20 years before disease onset.
  • The paper states that more than 30% of AD cases could be due to modifiable risk factors, and cites a report identifying 12 modifiable risk factors that account for about 40% of dementias worldwide.
  • Current approved AD drugs are four symptomatic medications: donepezil, memantine, galantamine, and rivastigmine; the paper says their effects are only partial and temporary.
  • The review highlights soft nanoparticles as delivery tools: liposomes and exosomes are presented as capable of crossing the BBB, and intranasal administration is described as a promising route; however, no nanosystem has passed the clinical development stage for intranasal delivery.

Methods

  • Narrative review of the literature on AD clinical spectrum, pathophysiology, risk factors, models, treatments, and delivery strategies.
  • Synthesizes findings from human studies, clinical trials, in vitro models, animal models, and nanotechnology/drug-delivery studies cited throughout the paper.
  • Main analysis is qualitative and comparative rather than experimental, organizing evidence into prevention, modeling, treatment limitations, and BBB-delivery approaches.

Limitations

  • Stated by the paper: current treatment effects are symptomatic, partial, and temporary, and there is no curative treatment or disease-modifying treatment yet.
  • Stated by the paper: evidence for prevention and intranasal approaches is limited by short study durations, inconsistent results, and the fact that no nanosystem has passed clinical development.
  • Evident from the text: this is a broad review, so its conclusions depend on heterogeneous prior studies and do not present new primary data or a formal meta-analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms232213954

Cites

274 of 274 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Alzheimer’s Disease spectrum. (A) Key players in the pathogenesis of Alzheimer’s disease (AD). Reprinted with permission from [12]. Copyright 2009, Nature Publishing Group. (B) Aging and metabolic diseases alteration of brain metabolism, which progressively causes AD. Reprinted from [65], Copyright 2017, Yonsei University College of Medicine. (C) Differential diagnosis of AD using neuroimaging biomarkers. Reprinted with permission [66]. Copyright 2009, Elsevier.
Figure 1 Alzheimer’s Disease spectrum. (A) Key players in the pathogenesis of Alzheimer’s disease (AD). Reprinted with permission from [12]. Copyright 2009, Nature Publishing Group. (B) Aging and metabolic diseases alteration of brain metabolism, which progressively causes AD. Reprinted from [65], Copyright 2017, Yonsei University College of Medicine. (C) Differential diagnosis of AD using neuroimaging biomarkers. Reprinted with permission [66]. Copyright 2009, Elsevier.CC BY · PubMed Central
Figure 2 3D in vitro models of Alzheimer’s disease. (A) PLGA scaffold encapsulating iPSC-derived NPCs, shown by proliferation marker Ki67, undifferentiated cell marker Nestin, and neural differentiation marker TuJ1. (i–iii) Cross-section ofthe 3D microfiber scaffold showing cell infiltration, distribution and differentiation. (iv,v) cell proliferation and differentiation. (vi) SEM image of the scaffold cross-section. Reprinted with permission from [134]. Copyright 2020, The Royal Society of Chemistry. (B) Reduction of neural plasticity in neural stem cells as a result of Aβ plaques. Image (i,iii) indicate healthy neural stem cells, which can form new synaptic connections, shown in (iii). Image (ii,iv) have the Aβ plaques incorporated in the hydrogel and are unable to form new synaptic connections. Reprinted with permission from [135]. Copyright 2018, Elsevier. (C) 3D spheroids derived from human neural progenitor cells, displaying Aβ pathology (shown in blue). Green and Red channels depict the neuronal cells and differentiated neurons, respectively. Reprinted from [138]. Copyright 2020, Nature Portfolio. (D) Acoustofluidic platform to assemble cells and Aβ oligomers into neuro-spheroids representing AD. Reproduced with permission of The Royal Society of Chemistry [139]. (i) cross-section of the 3D microfiber scaffold after sectioning (dotted line indicates the top surface of the 3D scaffold); (ii,iii) cell infiltration, distribution and differentiation of iPSC-derived NPCs (8529 cell line) inside the 3D scaffold as assessed via staining for TuJ1 (green) and Nestin (red) markers on D13; (iv) cell proliferation assessed by the Ki67 (green) marker and (v) cell differentiation with neurite formation indicated by the TuJ1 (red) marker of hESC-derived NPCs on D13; nuclei were counterstained with DAPI (blue); (vi) SEM image of the scaffold cross-section showing cell morphology and attachment on microfibers at 2000× magnification.
Figure 2 3D in vitro models of Alzheimer’s disease. (A) PLGA scaffold encapsulating iPSC-derived NPCs, shown by proliferation marker Ki67, undifferentiated cell marker Nestin, and neural differentiation marker TuJ1. (i–iii) Cross-section ofthe 3D microfiber scaffold showing cell infiltration, distribution and differentiation. (iv,v) cell proliferation and differentiation. (vi) SEM image of the scaffold cross-section. Reprinted with permission from [134]. Copyright 2020, The Royal Society of Chemistry. (B) Reduction of neural plasticity in neural stem cells as a result of Aβ plaques. Image (i,iii) indicate healthy neural stem cells, which can form new synaptic connections, shown in (iii). Image (ii,iv) have the Aβ plaques incorporated in the hydrogel and are unable to form new synaptic connections. Reprinted with permission from [135]. Copyright 2018, Elsevier. (C) 3D spheroids derived from human neural progenitor cells, displaying Aβ pathology (shown in blue). Green and Red channels depict the neuronal cells and differentiated neurons, respectively. Reprinted from [138]. Copyright 2020, Nature Portfolio. (D) Acoustofluidic platform to assemble cells and Aβ oligomers into neuro-spheroids representing AD. Reproduced with permission of The Royal Society of Chemistry [139]. (i) cross-section of the 3D microfiber scaffold after sectioning (dotted line indicates the top surface of the 3D scaffold); (ii,iii) cell infiltration, distribution and differentiation of iPSC-derived NPCs (8529 cell line) inside the 3D scaffold as assessed via staining for TuJ1 (green) and Nestin (red) markers on D13; (iv) cell proliferation assessed by the Ki67 (green) marker and (v) cell differentiation with neurite formation indicated by the TuJ1 (red) marker of hESC-derived NPCs on D13; nuclei were counterstained with DAPI (blue); (vi) SEM image of the scaffold cross-section showing cell morphology and attachment on microfibers at 2000× magnification.CC BY · PubMed Central
Figure 3 Schematic representation of liposomes, inorganic and polymeric nanoparticles crossing the BBB. Created with BioRender.com.
Figure 3 Schematic representation of liposomes, inorganic and polymeric nanoparticles crossing the BBB. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

73 Valid · 2 Not valid · 37 Not checked · 45 Own results and interpretations

68 more claims · 31 with their cited sources checked

Create a free account to see all 157 claims and to verify the 10 references still open.

See all claims — free account
  • It may state two separate claims as one. 73
  • Probably not a substantial claim. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Items 201–274 of 274

Research works printed but not linked: 1

  1. Prince, M.J., Guerchet, M.M., and Prina, M. (2022, June 04). The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing. Available online: https://hal.archives-ouvertes.fr/hal-03517019.

Cited by

See all 689

Metadata

Authors
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E.
Affiliations
  • Laboratoire Animal et Agroécosystèmes (FR)
  • Laboratoire d'Ingénierie des Biomolécules (FR)
  • University of Twente (NL)
  • UConn Health (US)
  • LIBio Laboratory, University of Lorraine, 54505 Vandoeuvre-lès-Nancy, France
Corresponding author
Yen, Frances T.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-11-12
Volume
23
Issue
22
Pages
13954
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4309008621
Cited by
689
References
279
Citations by year
2026: 204 · 2025: 255 · 2024: 171 · 2023: 58 · 2022: 1
FWCI
13.82
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Twente Research Information (publishedVersion, cc-by)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Twente Research Information (submittedVersion, cc-by)
Funders
Agence Nationale de la Recherche (ANR-15-IDEX-0004)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, Alzheimer's disease prevention, risk factors, disease-modifying therapy, brain drug delivery, blood-brain barrier, nanoliposomes, exosomes, nanoparticles, intranasal administration
MeSH terms
Alzheimer Disease, Blood-Brain Barrier, Humans, Drug Delivery Systems, Neurodegenerative Diseases, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.